文献速递脑血管病

直接口服抗凝药治疗中突破性缺血性卒中后的抗凝策略:一项荟萃分析

Anticoagulation Strategies Following Breakthrough Ischemic Stroke While on Direct Anticoagulants: A Meta-Analysis.
PubMed 文献 · Neurology · 2025-08-04

该荟萃分析纳入8项观察性研究共14,307例患者,比较DOAC治疗中发生缺血性卒中后不同抗凝策略。结果显示,换用华法林较维持原DOAC或更换DOAC剂量增加缺血性卒中及颅内出血风险,而维持原DOAC与换用另一种DOAC结局相似。

要点

  • DOAC治疗中发生卒中后换用华法林增加复发缺血性卒中风险。
  • 换用华法林较维持DOAC或换用另一种DOAC增加颅内出血风险。
  • 维持原DOAC与换用另一种DOAC的临床结局相似。

核心结论

  • DOAC治疗中发生卒中后换用华法林在预防卒中复发、颅内出血和死亡方面似乎不如基于DOAC的策略有效和安全。

研究设计与样本

  • 系统检索MEDLINE、Scopus和Cochrane Library截至2025年1月31日的文献,纳入样本量≥50的随机对照研究和队列研究,最终8项观察性研究进入定量合成,共14,307例患者,平均年龄75岁,女性48%。

主要发现

  • 换用华法林较维持原DOAC增加缺血性卒中风险(RR 1.80,95% CI 1.42-2.29,I2=0%,5项研究)。
  • 换用华法林较更换DOAC剂量增加缺血性卒中风险(RR 1.72,95% CI 1.20-2.45,I2=0%,4项研究)。
  • 换用华法林较维持原DOAC增加颅内出血风险(RR 2.90,95% CI 2.01-4.18,I2=0%,5项研究)。
  • 换用华法林较DOAC换用DOAC增加颅内出血风险(RR 3.25,95% CI 2.13-4.96,I2=0%,5项研究)。
  • 维持原DOAC与换用另一种DOAC的主要和次要结局发生率相似。

临床怎么用

  • 对于DOAC治疗中发生缺血性卒中的患者,避免换用华法林可能更安全有效。
  • 维持原DOAC或换用另一种DOAC可作为抗凝策略调整的优先选择。

局限性

  • 纳入研究均为观察性研究,存在 confounding 可能。
  • 未报告随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The management of anticoagulation after ischemic stroke while on direct oral anticoagulants (DOACs) is controversial. We performed an aggregate-data meta-analysis to compare anticoagulation strategies against each other to define the effect of switch to warfarin, switch to another DOAC, change in dosage, and add-on antiplatelet for the prevention of recurrent stroke, intracranial hemorrhage (ICH), any stroke, and mortality. METHODS: The study protocol was deposited with PROSPERO (CRD42025639057). We systematically searched MEDLINE, Scopus, and the Cochrane Library-all studies reporting on anticoagulation strategies after a stroke while on DOAC up to January 31, 2025. We included randomized controlled clinical studies and cohort studies with sample size ≥50 that (1) enrolled adult patients who experienced ischemic stroke while on DOACs, (2) assessed modifications to anticoagulation therapy, and (3) reported on at least one of the outcomes. Main outcome was recurrent ischemic stroke; secondary outcomes were ICH, all-cause mortality, and any stroke. We pooled estimates by random-effects modelling, reporting risk ratio (RR) with 95% CIs comparing anticoagulation strategies against each other. RESULTS: We retrieved 2,171 results, with 8 observational studies reaching quantitative synthesis (n = 14,307 patients, mean age = 75 years, 48% female). Switching to warfarin was associated with a higher risk of ischemic stroke compared with keeping the same DOAC (RR 1.80, 95% CI 1.42-2.29, I2 = 0%, nstudies = 5) or changing DOAC dosage (RR 1.72, 95% CI 1.20-2.45, I2 = 0%, nstudies = 4). Switching to warfarin was also associated with higher ICH rates compared with keeping the same DOAC (RR 2.90, 95% CI 2.01-4.18, I2 = 0%, nstudies = 5) and DOAC-to-DOAC switch (RR 3.25, 95% CI 2.13-4.96, I2 = 0%; nstudies = 5). Keeping the same DOAC and switching to another DOAC, independently from mechanism, had similar rates of primary and secondary outcomes. DISCUSSION: Our meta-analysis indicates that switching to warfarin after a stroke while on DOAC seems less effective and safe in stroke recurrence prevention, ICH, and mortality compared with DOAC-based strategies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Romoli M, Paciaroni M, Marrone N, et al. Anticoagulation Strategies Following Breakthrough Ischemic Stroke While on Direct Anticoagulants: A Meta-Analysis. Neurology. 2025. PMID: 40758940. doi:10.1212/WNL.0000000000213964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。